Comparative Pharmacology
Head-to-head clinical analysis: RAYALDEE versus ZEMPLAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RAYALDEE versus ZEMPLAR.
RAYALDEE vs ZEMPLAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Rayaldee (calcifediol) is a vitamin D3 analog that is converted to the active hormone calcitriol by 1-alpha-hydroxylase in the kidney. It acts as a vitamin D receptor agonist, increasing intestinal absorption of calcium and phosphate, promoting renal tubular reabsorption of calcium, and suppressing parathyroid hormone (PTH) secretion. In CKD patients, it lowers elevated PTH levels.
Vitamin D receptor agonist; binds to vitamin D receptors, regulating gene expression of calcium-binding proteins and cellular proliferation/differentiation.
30 mcg orally once daily at bedtime.
0.04-0.1 mcg/kg IV three times weekly; titrate to serum calcium. Oral: 1-2 mcg daily or 0.5-1 mcg three times weekly.
None Documented
None Documented
Terminal elimination half-life is approximately 14-19 hours, reflecting the extended-release formulation designed for once-daily dosing.
Terminal elimination half-life is 5–7 hours in healthy subjects; prolonged to 14–21 hours in patients with chronic kidney disease stage 5 on hemodialysis, reflecting reduced clearance.
Primarily fecal via biliary excretion (70-80%); renal excretion accounts for <10% of total clearance.
Primarily hepatobiliary (74% of absorbed dose recovered in feces as parent drug and metabolites); renal excretion accounts for approximately 16% (primarily as metabolites).
Category C
Category C
Vitamin D Analog
Vitamin D Analog